Momentum Health 360 carries a June 2026 federal warning letter that names its own website and its establishment identifier. Its catalogue prices five tracked compounds in the open, but the NAD+ one-month lane renders no figure at all, so the cheapest term on that product cannot be seen.
What Momentum Health 360 charges
NAD+: $175/mo — per month, "Billed monthly", on the two-month plan; the shop catalogue prints "Starting from $185.00" for the same product and the one-month lane renders no figure
Sermorelin: $249 — starting from; the catalogue names no billing period
Glutathione: $149 — starting from; the catalogue names no billing period
Semaglutide: $325 — starting from; the catalogue names no billing period
Tirzepatide: $499 — starting from; the catalogue names no billing period
Momentum Health 360 is not a paid partner; this link may earn a commission if that changes. Full disclosure.
By Nora Castellan, Standards EditorUpdated September 2026
The federal letter names the website and the establishment identifier
The letter's own opening says violations were identified during a review of this seller's website, naming the address and its FDA establishment identifier, in March 2026.
It says the site offers compounded drug products including semaglutide, tirzepatide and liraglutide, and the recipient block is in Newport Beach, California.
That is how the letter was matched here — from the body of the letter itself, not from a similar name in the federal table.
One price lane renders nothing at all
The NAD+ product page offers plan selectors for one, two and three months. The two-month lane renders a per-month figure marked billed monthly under a savings heading.
The one-month lane renders no figure. In its place the page prints that it is refreshing options for this selection and suggests trying another plan or checking back shortly.
So the shortest and least committed term is the one term a reader cannot price. That is recorded as a fault rather than smoothed over.
The product page and the catalogue disagree, and four figures name no period
The shop catalogue prints a starting-from figure for NAD+ that is higher than the two-month plan figure on the product page. Both are the seller's and both are recorded.
Its sermorelin, glutathione, semaglutide and tirzepatide figures are catalogue floors with a duration selector behind them and no cycle printed, so all four are recorded here as not monthly.
That leaves exactly one of its five prices carrying a stated billing period.
What it says about legal category
In its own words: "The treatments offered through Momentum Health 360 include compounded medications, prepared by state-licensed compounding pharmacies based on your prescription."
The same passage continues: "Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality."
It names a pharmacy class rather than a pharmacy, and publishes no certificate of analysis.
Who it's for
Readers who want an open catalogue with no intake standing in front of the prices.
Buyers comparing five tracked compounds from one seller in one place.
Anyone who wants plan lengths from one to six months offered on the product page itself.
Shoppers who read the federal letter alongside the price sheet.
Who should look elsewhere
Readers who need a price for the shortest NAD+ term.
Buyers who need to know whether a catalogue floor covers a month or an order.
Anyone who will not order from a seller carrying a recent federal warning letter.
Shoppers who want the dispensing pharmacy named.
Strengths
Prices five tracked compounds individually on an open catalogue with no intake in the way
States in its own words that its compounded medicines are not FDA-approved
Prints "Billed monthly" beside the one figure that is a monthly figure
Offers plan lengths from one to six months on the product page itself
Trade-offs
Carries a June 2026 federal warning letter naming its own website and establishment identifier
Its NAD+ one-month lane renders no price at all, so the cheapest term cannot be seen
The NAD+ product page and the shop catalogue print different figures for the same product
Its catalogue floors name no billing period, so four of its five prices are periodless
FDA disclosure
Momentum Health 360 received an FDA warning letter issued June 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
How we verified this
Stepped through the NAD+ plan selector and confirmed the two-month lane renders a figure while the one-month lane renders a refreshing-options message instead.
Compared the NAD+ product page against the shop catalogue, found two different figures for the same product, and recorded both rather than reconciling them.
Read each catalogue floor and confirmed no billing cycle is printed, then recorded four of the five prices as not monthly.
Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
Confirmed the federal warning letter from its own opening line, which names this seller's website and its establishment identifier, rather than from a name match against the federal table.
A provider to compare Momentum Health 360 against
Trellis Vitality
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
The one-month lane renders no figure. The page prints a message about refreshing options and suggests trying another plan, so the cheapest term is unpriced.
Which NAD+ figure is correct?
Unresolved. The product page's two-month plan and the shop catalogue print different figures for the same product, and neither page corrects the other.
Are the catalogue prices monthly?
No. Its sermorelin, glutathione, semaglutide and tirzepatide figures are starting-from floors with a duration selector behind them and no cycle printed.
What does the warning letter say?
It says the agency reviewed this seller's website and establishment identifier in March 2026 and observed compounded drug products offered there, including semaglutide, tirzepatide and liraglutide.
Momentum Health 360 is not a paid partner; this link may earn a commission if that changes. Full disclosure.